Using 68Ga-FAPI PET/CT to assess spondyloarthritis
Characterizing Spondyloarthritis With 68Ga-FAPI PET/CT
This study is testing if a new type of imaging called 68Ga-FAPI PET/CT can better detect inflammation in the joints of adults with spondyloarthritis compared to standard imaging methods.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | The First Affiliated Hospital of Xiamen University Academic / other |
| Locations | 1 site (Xiamen, Fujian) |
| Trial ID | NCT05999643 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of 68Ga-FAPI PET/CT imaging in diagnosing spondyloarthritis and assessing inflammation in affected joints. Spondyloarthritis is a chronic inflammatory condition that can severely impact quality of life, and current diagnostic methods may not always be sufficient. The study aims to determine if 68Ga-FAPI PET/CT can provide better sensitivity in detecting inflammation compared to traditional imaging techniques. Participants will include adults diagnosed with spondyloarthritis who meet specific inclusion criteria.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 65 with a confirmed diagnosis of spondyloarthritis.
Not a fit: Patients who are pregnant, breastfeeding, or have known allergies to FAPI may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy and treatment monitoring for patients with spondyloarthritis.
How similar studies have performed: Previous studies have shown that 68Ga-FAPI PET/CT is more sensitive than traditional methods in detecting inflammation in related conditions, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. A diagnosis of SpA according to the ASAS (Assessment of Spondyloarthritis International Society) classification criteria for SpA. 2. Adult men or women 18 and ≤ 65 years of age at the time of signing the informed consent (ICF). 3. participants who were able to provide informed consent (signed by participant or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: 1. Pregnancy; 2. Breastfeeding; 3. known allergy against FAPI; 4. any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Where this trial is running
Xiamen, Fujian
- The first affiliated hospital of Xiamen University — Xiamen, Fujian, China (Recruiting)
Study contacts
- Study coordinator: Yuan Liu, MD
- Email: iuyuan@xmu.edu.cn
- Phone: 86 0592-2137749
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.